Patents by Inventor Francesco Tedesco

Francesco Tedesco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to ?2-glycoprotein I and therapeutic uses thereof
    Patent number: 9777057
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 3, 2017
    Assignee: ONCONOX APS
    Inventors: Francesco Tedesco, Pier Luigi Meroni, Daniele Sblattero
  • ANTIBODIES TO ß2-GLYCOPROTEIN I AND THERAPEUTIC USES THEREOF
    Publication number: 20160152696
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Application
    Filed: July 7, 2014
    Publication date: June 2, 2016
    Applicant: ONCONOX APS
    Inventors: Francesco TEDESCO, Pier Luigi MORONI, Daniele SBLATTERO
  • Anti-C5 alpha antibodies
    Patent number: 8962819
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Adienne S.A.
    Inventors: Francesco Tedesco, Roberto Marzari
  • Anti-C5 Alpha Antibodies
    Publication number: 20130071922
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: Adienne SRL
    Inventors: Francesco TEDESCO, Roberto Marzari
  • Methods of treating a disease with anti-C5 alpha antibodies
    Patent number: 8282929
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterized by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 9, 2012
    Assignee: Adienne SRL
    Inventors: Francesco Tedesco, Roberto Marzari
  • Anti-C5 Alpha Antibodies
    Publication number: 20120009184
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: July 18, 2011
    Publication date: January 12, 2012
    Applicant: ADDIENE SRL
    Inventors: Francesco TEDESCO, Roberto Marzari
  • Recombinant antibodies against CD55 and CD59 and uses thereof
    Patent number: 8034902
    Abstract: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: October 11, 2011
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roberto Marzari, Daniele Sblattero, Francesco Tedesco
  • Anti-C5 alpha antibodies
    Patent number: 7999081
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: August 16, 2011
    Assignee: Adienne SRL
    Inventors: Francesco Tedesco, Roberto Marzari
  • Recombinant antibodies against cd55 and cd59 and uses thereof
    Publication number: 20090053225
    Abstract: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
    Type: Application
    Filed: May 1, 2006
    Publication date: February 26, 2009
    Inventors: Roberto Marzari, Daniele Sblattero, Francesco Tedesco
  • Antibodies anti-c5 component of the complement system and their use
    Publication number: 20060115476
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: July 10, 2003
    Publication date: June 1, 2006
    Inventors: Francesco Tedesco, Roberto Marzari